Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.

作者信息

Donovan Jeffrey C, Ghazarian Danny M, Shaw James C

出版信息

Arch Dermatol. 2008 Nov;144(11):1524-5. doi: 10.1001/archderm.144.11.1524.

DOI:10.1001/archderm.144.11.1524

PMID:19015435

Abstract

摘要

相似文献

Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.

Arch Dermatol. 2008 Nov;144(11):1524-5. doi: 10.1001/archderm.144.11.1524.

Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.

J Am Acad Dermatol. 2011 May;64(5):996-8. doi: 10.1016/j.jaad.2009.08.024.

Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.

J Clin Oncol. 2013 Jul 10;31(20):e335-7. doi: 10.1200/JCO.2012.46.9346. Epub 2013 May 28.

Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.

J Am Acad Dermatol. 2006 Aug;55(2):349-53. doi: 10.1016/j.jaad.2005.12.016.

A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.

J Cutan Pathol. 2009 Dec;36(12):1303-7. doi: 10.1111/j.1600-0560.2009.01275.x. Epub 2009 Jun 9.

Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.

Clin Lung Cancer. 2003 Sep;5(2):83-5. doi: 10.1016/S1525-7304(11)70324-2.

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.

Lung Cancer. 2006 Jan;51(1):89-96. doi: 10.1016/j.lungcan.2005.09.002. Epub 2005 Nov 14.

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

J Clin Oncol. 2003 Jul 15;21(14):2658-63. doi: 10.1200/JCO.2003.01.039.

Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.

Pharmacogenet Genomics. 2007 May;17(5):313-9. doi: 10.1097/FPC.0b013e328011abc0.

Gefitinib. Still no convincing results in non-small cell lung cancer.

Prescrire Int. 2010 Jun;19(107):113.

引用本文的文献

Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile.

Pharmaceuticals (Basel). 2024 Aug 7;17(8):1040. doi: 10.3390/ph17081040.

Dermatologic conditions in women receiving systemic cancer therapy.

Int J Womens Dermatol. 2019 Nov 7;5(5):285-307. doi: 10.1016/j.ijwd.2019.10.003. eCollection 2019 Dec.

Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.

Dermatol Res Pract. 2014;2014:734249. doi: 10.1155/2014/734249. Epub 2014 Mar 2.

A comparison of epithelial-to-mesenchymal transition and re-epithelialization.

Semin Cancer Biol. 2012 Oct;22(5-6):471-83. doi: 10.1016/j.semcancer.2012.07.003. Epub 2012 Jul 31.

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.

Support Care Cancer. 2012 May;20(5):909-21. doi: 10.1007/s00520-012-1404-0. Epub 2012 Feb 24.

A case of cicatricial alopecia associated with erlotinib.

Ann Dermatol. 2011 Dec;23(Suppl 3):S350-3. doi: 10.5021/ad.2011.23.S3.S350. Epub 2011 Dec 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验